Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Epi Data Slicer
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key bladder cancer patient populations covering 171 countries and more than…